Prognosis of Stage A or B Heart Failure Patients With Elevated B-type Natriuretic Peptide Levels

Journal of Cardiac Failure

Volumn 16, Issue 2, 2010, Pages 93-98

  Daniels, Lori B ^a   Clopton, Paul ^a,b   Jiang, Kevin ^b   Greenberg, Barry ^a   Maisel, Alan S ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Biomarkers; echocardiography; risk stratification

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COLOR ULTRASOUND FLOWMETRY; DEATH; FEMALE; HEART FAILURE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; TISSUE DOPPLER IMAGING;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 74049134122     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2009.10.020     Document Type: Article

References (16)

1. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Leip E.P., Omland T., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350 (2004) 655-663
2. Kistorp C., Raymond I., Pedersen F., Gustafsson F., Faber J., and Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293 (2005) 1609-1616
3. Daniels L.B., Laughlin G.A., Clopton P., Maisel A.S., and Barrett-Connor E. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 52 (2008) 450-459
4. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 (2005) 1440-1463
5. Fiegenbaum H. Echocardiography. 6th ed. (1999), Lea and Febiger, Philadelphia, PA
6. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
7. Garcia M.J., Thomas J.D., and Klein A.L. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 32 (1998) 865-875
8. Schocken D.D., Benjamin E.J., Fonarow G.C., Krumholz H.M., Levy D., Mensah G.A., et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117 (2008) 2544-2565
9. Hunt S.A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) e1-82
10. Sheen V., Bhalla V., Tulua-Tata A., Bhalla M.A., Weiss D., Chiu A., et al. The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J 153 244 (2007) e1-e5
11. Wu A.H., Packer M., Smith A., Bijou R., Fink D., Mair J., et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem 50 (2004) 867-873
12. Rodeheffer R.J., Jacobsen S.J., Gersh B.J., Kottke T.E., McCann H.A., Bailey K.R., et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc 68 (1993) 1143-1150
13. Ho K.K., Anderson K.M., Kannel W.B., Grossman W., and Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88 (1993) 107-115
14. Ammar K.A., Jacobsen S.J., Mahoney D.W., Kors J.A., Redfield M.M., Burnett Jr. J.C., et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation 115 (2007) 1563-1570
15. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 (1992) 685-691
16. Heidenreich P.A., Gubens M.A., Fonarow G.C., Konstam M.A., Stevenson L.W., and Shekelle P.G. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 43 (2004) 1019-1026